United Therapeutics reports $832.5M Q3 2026 revenue, up 4% YoY
United Therapeutics reported total revenue of $832.5 million for the quarter ended September 30, 2026, a 4% increase from the prior year. The company's results reflect strong commercial momentum driven by Tyvaso DPI, though net income declined due to higher operating expenses.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed